Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. acute ischemic stroke confirmed by diffusion weighted imaging~2. transient ischemic attack (TIA) within 7 days~Exclusion Criteria:~1. there is intracranial hemorrhage on imaging study~2. patients is previously taking antiplatelets, vitamin K antagonists, factor Xa antagonists, or chronic treatment with systemic steroidal and non-steroidal anti-inflammatory drugs~3. patients who received fibrinolytics within the previous 48 hours~4. cognitive impairment interfering with the possibility of obtaining informed consent~5. pregnancy~6. participation in another pharmacological study~7. peptic ulcer disease or hematological abnormality~8. initial modified Barthel index \<30 points~9. liver function tests exceeding a 2-fold upper range value.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cilostazol group (Type: EXPERIMENTAL): aspirin placebo daily and 100 mg cilostazol twice daily
- aspirin group (Type: ACTIVE_COMPARATOR): 100 mg aspirin daily and cilostazol placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).